LGND

Ligand Pharmaceuticals Incorporated

Healthcare · Biotechnology · NGM
$255.54
Data: 2026-06-14
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Convergence Score
Score pending — view screener
Market Regime
Analysis pending
Today's Read
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-03
Full Daily Analysis

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$5.1B
Total market value of the company
Trailing P/E
33.27
Premium valuation
Forward P/E
22.58
Based on estimated future earnings — lower means cheaper
Rev Growth
+14.1%
Year-over-year revenue change
Profit Margin
56.0%
How much profit the company keeps from each dollar of revenue
ROE
17.1%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$278.50
+9% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 10 analysts covering this stock

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also pr

https://www.ligand.com

Country: United States Employees: 47 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
1.517
Excellent risk-adjusted returns
Kelly Fraction
0.1235
Suggested allocation is meaningful — the edge justifies a position
Calmar Ratio
2.608
Returns exceed worst-case losses — strong risk profile
Annual Return
66.7%
Historical annualised return based on price data
Max Drawdown
-25.6%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
1
How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta
1.04
Moves slightly more than the broader market
52W High
$259.03
1% below the year high
52W Low
$110.00
132% above the year low
Avg Volume
221,314
Average daily shares traded — higher means easier to buy and sell
Short Ratio
7.5
Days it would take all short sellers to cover — higher means more crowded
Short % Float
9.0%
Moderate short interest
Div Yield
N/A
Annual dividend as a percentage of the share price
EPS (TTM)
$7.68
Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
45.32
Heavy leverage — higher financial risk if revenues decline
Current Ratio
21.28
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
20.81
Like current ratio but excludes inventory — stricter test
Gross Margin
83.2%
Revenue left after cost of goods — higher means pricing power
Operating Margin
33.6%
Profit from core operations before interest and tax
Free Cash Flow
$142M
Positive — the business generates more cash than it spends
Revenue (TTM)
$274M
Total revenue over the last 12 months
Net Income
$154M
Profitable — the bottom line is positive

Analyst Coverage

Analysts
10
Target High
$330.00
Target Median
$278.50
Target Low
$247.00

What If You'd Bought LGND?

Period Price Then Price Return Divs/Share $1,000 Became Total Return
1 Month $220.48 +12.9% — $1,129 +12.9%
2 Months $204.92 +21.5% — $1,215 +21.5%
3 Months $211.48 +17.7% — $1,177 +17.7%
6 Months $183.13 +36.0% — $1,360 +36.0%
1 Year $113.42 +119.5% — $2,195 +119.5%
2 Years $79.53 +213.1% — $3,131 +213.1%
3 Years $73.76 +237.6% — $3,376 +237.6%
5 Years $77.12 +222.9% — $3,229 +222.9%

Historical returns. Past performance does not guarantee future results. Prices from market close data.

Framework Review History

Timestamped framework reads — tracking how the analysis evolves over time

2026-07-03 MARKUP $255.54 +0.0% Review #2

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.

2026-07-02 MARKUP $255.54 Review #1

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.

Latest Analysis — LGND

Timestamped intelligence from our daily research pipeline

3 Jul 2026
08:56 UTC
Uncategorized
LGND — Deep Ticker Analysis | Framework Read 3 July 2026

Ligand Pharmaceuticals (LGND) — Markup at $255.54 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container...

3 Jul 2026
08:40 UTC
Uncategorized
LGND — Deep Ticker Analysis | Framework Read 3 July 2026

Ligand Pharmaceuticals (LGND) — Markup at $255.54 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container...

3 Jul 2026
05:48 UTC
Uncategorized
LGND — Deep Ticker Analysis | Framework Read 3 July 2026

Ligand Pharmaceuticals (LGND) — Markup at $255.54 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container...

3 Jul 2026
05:45 UTC
Uncategorized
LGND — Deep Ticker Analysis | Framework Read 3 July 2026

Ligand Pharmaceuticals (LGND) — Markup at $255.54 with 70.0 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container...

27 Jun 2026
08:31 UTC
Pre-Asia Brief
Titan 25 Q3 2026: IAMGOLD Leads as Gold Hits $4,100 — All 25 Stocks Pass Ethical Screening

Titan Research Desk  |  Weekly Review  |  27 June 2026 Titan 25 Weekly Review: Q3 Opens With 100% Ethical Compliance and Gold at the Top As Q2 closes and Q3...

View all daily analysis →
Want deeper analysis on Ligand Pharmaceuticals Incorporated?
Our framework analyses LGND daily across 19 analytical perspectives — positioning, macro, sentiment, volatility, options, sector rotation, and more. Members get the read 24 hours before anyone else.
Start Free — Explorer Access Open the Convergence Screener View Our Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-14

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry Indicators Options Calendar Composites Boycott Tracker Convergence Screener Fed Tracker Explore All Is It Halal? Earnings Calendar Dividend Screener Country Guides Glossary Join Free →

Get our weekly market brief free.